Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 2, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 2, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001817199-26-000032
Filed / recorded
Oct 2, 2026, 9:21 PM UTC
Added to OQRO
Oct 7, 2026, 2:00 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Nurix Therapeutics, Inc.
Issuer CIK
1549595
Ticker
NRIX
Reporting person
Christine Ring
Relationship
Officer
Officer title
Chief Legal Officer
Security
Employee Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Oct 2, 2026
Transaction code
M
Shares / units
5,786
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
111,251
Ownership form
Direct
Amendment
No
Footnotes from the filing
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.